Compare LTC & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | LMAT |
|---|---|---|
| Founded | 1992 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 1994 | 2006 |
| Metric | LTC | LMAT |
|---|---|---|
| Price | $41.21 | $80.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $40.00 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 442.2K | 311.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.96% | 0.93% |
| EPS Growth | 23.53 | ★ 30.57 |
| EPS | 1.05 | ★ 1.42 |
| Revenue | ★ $262,854,000.00 | $249,602,000.00 |
| Revenue This Year | N/A | $14.21 |
| Revenue Next Year | N/A | $8.88 |
| P/E Ratio | ★ $39.59 | $57.28 |
| Revenue Growth | ★ 25.26 | 13.53 |
| 52 Week Low | $33.64 | $78.27 |
| 52 Week High | $43.00 | $118.01 |
| Indicator | LTC | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 61.18 | 40.04 |
| Support Level | $37.67 | $78.77 |
| Resistance Level | $43.00 | $88.35 |
| Average True Range (ATR) | 0.65 | 2.07 |
| MACD | 0.14 | 0.63 |
| Stochastic Oscillator | 87.94 | 50.49 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.